GlassScriptPhysician profile
Jesse W Couk
NPI 1710114335
$5,555.77
in general payments reported to CMS, 2019-2025
28 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $398 · 2021: $419 · 2022: $504 · 2023: $811 · 2024: $1,035 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,110 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,110.04 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,436.41 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $804.98 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $695.17 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Insmed, INC. | $408.74 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $333.62 | 2021-2025 | Mavyret |
| La Jolla Pharmaceutical Company | $276.94 | 2021-2025 | Xerava, Zevtera |
| Melinta Therapeutics, LLC | $216.84 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Janssen Biotech, INC. | $188.10 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $158.39 | 2019-2025 | Mytesi |
| Theratechnologies INC. | $144.58 | 2019-2025 | Egrifta, Trogarzo |
| Ferring Pharmaceuticals INC. | $134.51 | 2023-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $103.14 | 2023-2025 | Vowst |
| Paratek Pharmaceuticals, INC. | $100.99 | 2024-2025 | Nuzyra |
| Tetraphase Pharmaceuticals, INC. | $80.67 | 2019-2025 | |
| Dynavax Technologies Corporation | $75.04 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $67.74 | 2024 | Cresemba |
| Cumberland Pharmaceuticals, INC. | $67.26 | 2019-2025 | Vibativ |
| Angiodynamics, INC. | $49.64 | 2025 | Angiovac |
| Janssen Scientific Affairs, LLC | $36.04 | 2019 | |
| Pfizer INC. | $28.89 | 2025 | |
| Hologic Sales and Service, LLC | $23.88 | 2024 | Aptima |
| Alexion Pharmaceuticals, INC. | $22.29 | 2021 | |
| Shionogi INC | $21.32 | 2022 | |
| Stryker Corporation | $20.83 | 2021 | |
| Mayne Pharma Commercial LLC | $18.81 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.78 | 2024 | Xifaxan, Trulance |
| Hydrofera LLC | $12.91 | 2023 | Hydrofera Blue |
| Allergan, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Couk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.